The BAFfling story of MN1-induced leukemogenesis

Aaron J Stonestrom; Ross L Levine

doi:10.1016/j.molcel.2021.05.001

The BAFfling story of MN1-induced leukemogenesis

Mol Cell. 2021 Jun 3;81(11):2268-2269. doi: 10.1016/j.molcel.2021.05.001.

Authors

Aaron J Stonestrom¹, Ross L Levine²

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA; Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA. Electronic address: leviner@mskcc.org.

Abstract

Riedel et al. (2021) show that expression of MN1 is capable of blocking myeloid differentiation and initiating leukemia through mechanisms that require Brg1-containing chromatin remodeling complexes. Intriguingly, this process depends on an unstructured polyglutamine repeat region within MN1.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Humans
Leukemia, Myeloid, Acute*
Meningeal Neoplasms*
Meningioma*
Trans-Activators
Tumor Suppressor Proteins

Substances

MN1 protein, human
Trans-Activators
Tumor Suppressor Proteins

Abstract

Publication types

MeSH terms

Substances

Grants and funding